var data={"title":"Ceftriaxone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ceftriaxone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5848?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ceftriaxone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ceftriaxone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftriaxone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rocephin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148199\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ceftriaxone for Injection;</li>\n      <li>Ceftriaxone for Injection USP;</li>\n      <li>Ceftriaxone Sodium for Injection;</li>\n      <li>Ceftriaxone Sodium for Injection BP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148250\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148203\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage range:</b> IM, IV: Usual dose: 1 to 2 g every 12 to 24 hours, depending on the type and severity of infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization (off-label use):</b> IV: 1 to 2 g every 12 to 24 hours (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arthritis, septic (off-label use):</b> IV: 1 to 2 g once daily (Coiffier 2014; Dalla Vestra 2008; Harwood 2008; Raad 2004). Additional data may be necessary to further define the role of ceftriaxone in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial enteric infections in HIV-infected patients (empiric treatment) (off-label use):</b> IV: 1 g every 24 hours (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal) (off-label use):</b> IV: 1 g every 12 hours in combination with clindamycin or metronidazole for anaerobic coverage (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess (off-label use):</b> IV: 2 g every 12 hours in combination with other antibiotics (Brouwer 2014; Louvois 2000). Additional data may be necessary to further define the role of ceftriaxone in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chancroid (off-label use):</b> IM: 250 mg as single dose (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholecystitis, mild-to-moderate:</b> IV: 1 to 2 g every 12 to 24 hours for 4 to 7 days (provided source controlled) (Solomkin 2010). <b>Note: </b>The addition of anaerobic therapy is recommended if biliary-enteric anastomosis is present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystitis (acute, complicated): </b>IV: 1 to 2 g once daily (Stamm 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prophylaxis (off-label use):</b> Dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): IM, IV: 1 g 30 to 60 minutes before procedure (AHA [Wilson 2007]). Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label use) (AHA [Baddour 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus, native or prosthetic valve (penicillin-susceptible/gentamicin-susceptible <b>or</b> penicillin-susceptible/aminoglycoside resistant)</i>: IV: 2 g every 12 hours for 6 weeks with concomitant ampicillin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HACEK organisms, native or prosthetic valve:</i> IV, IM: 2 g once daily for 4 weeks (native valve) or 6 weeks (prosthetic valve)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Viridans group Streptococcus (VGS) and S. bovis</i>: IV, IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Native valve:</i> Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 2 g once daily for 4 weeks <b>or</b> for 2 weeks with concomitant gentamicin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prosthetic valve:</i> Highly penicillin-susceptible (MIC &le;0.12 mcg/mL): 2 g once daily for 6 weeks (with or without concomitant gentamicin for the first 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prosthetic valve:</i> Relatively or fully penicillin-resistant (MIC &gt;0.12 mcg/mL): 2 g once daily with concomitant gentamicin for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epididymitis, acute (off-label use) (CDC [Workowski 2015]): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by sexually transmitted chlamydia and gonorrhea:</i> IM: 250 mg in a single dose plus doxycycline</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Likely caused by sexually transmitted chlamydia and gonorrhea and enteric organisms in men who practice insertive anal sex: </i>IM: 250 mg in a single dose plus oral levofloxacin or oral ofloxacin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Conjunctivitis (off-label use):</i></b> IM: 1 g in a single dose plus oral azithromycin; additionally, consider a one-time saline lavage of the infected eye. Data on treatment in adults are limited, consultation with an infectious-disease specialist should be considered (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Disseminated gonococcal infection (arthritis and arthritis-dermatitis syndrome) (off-label use):</i></b> IM, IV: 1 g once daily plus single dose oral azithromycin; continue for 24 to 48 hours after clinical improvement, then may switch to an oral agent guided by antimicrobial susceptibility to complete a total of at least 7 days of therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Endocarditis (off-label use):</i></b> IV: 1 to 2 g every 12 to 24 hours plus oral azithromycin; continue ceftriaxone for at least 28 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Meningitis (off-label use):</i></b> IV: 1 to 2 g every 12 to 24 hours plus oral azithromycin; continue ceftriaxone for 10 to 14 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>\n          <i>Uncomplicated gonorrhea: </i></i>\n        <i>\n          <i>Cervicitis, proctitis, urethritis (off-label</i>\n          <i>), pharyngitis (off-label)</i>\n          <i>:</i></i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dual-therapy regimen (preferred):</i> IM: 250 mg in a single dose plus oral azithromycin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment</i>\n      <i> failure: </i>\n      <b>Note:</b> Reinfections are more likely to occur than actual treatment failures, re-treatment with preferred dual-therapy regimen is recommended for re-infection. Consult with an infectious diseases specialist if treatment failure is suspected and report failures to the CDC (telephone: 404-639-8650), and state and local health departments (CDC [Workowski 2015]). Choice of agent (eg, ceftriaxone, gemifloxacin, or gentamicin) to combine with azithromycin following treatment failure varies considerably depending on the failed initial dual-therapy regimen, susceptibilities of isolate, and geographic location (CDC [Workowski 2015]; WHO [<i>Neisseria gonorrhoeae</i> 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment failure following single-therapy regimen or other non-preferred treatment regimens: </i>IM: 250 mg in a single dose plus azithromycin 1 g orally as a single dose (CDC [Workowski 2015], WHO [<i>Neisseria gonorrhoeae</i> 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment failure following initial therapy of an alternative dual therapy regimen (cefixime and azithromycin): </i>IM: 250 mg in a single dose plus azithromycin 2 g orally as a single dose (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment failure following initial therapy of the preferred dual-therapy regimen (ceftriaxone and azithromycin): </i>IM: 500 mg in a single dose plus azithromycin 2 g orally as a single dose (WHO [<i>Neisseria gonorrhoeae</i> 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection, complicated, community-acquired, mild-to-moderate (in combination with metronidazole):</b> IV: 1 to 2 g every 12 to 24 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (off-label use):</b> IV: 2 g once daily for 14 days (neurologic), or 21 to 28 days (carditis), or 28 days (arthritis with neurologic manifestations) (AAN [Halperin 2007]; IDSA [Wormser 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis, community-acquired (empiric treatment): </b> IV: 2 g every 12 hours for 7 to 14 days (longer courses may be necessary for selected organisms) in combination with other agents (eg, vancomycin) (IDSA [Tunkel 2004]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease, invasive, high-risk patient contacts (chemoprophylaxis) (off-label use):</b> IM: 250 mg in a single dose (CDC 2005; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Staphylococci, oxacillin-susceptible (off-label dose): 2 g every 24 hours for 6 weeks (IDSA [Berbari 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Streptococci (beta-hemolytic), <i>Cutibacterium acnes</i> or <i>Salmonella</i> spp (off-label use): IV: 2 g every 24 hours for 6 weeks. <b>Note:</b> In the treatment of <i>Salmonella</i> spp, a 6- to 8-week duration is recommended (IDSA [Berbari 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (mild to moderately severe):</b> IM: 250 mg in a single dose plus oral doxycycline (with or without oral metronidazole) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired (in combination with other antibiotics): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: IM, IV: 1 to 2 g/day in 1 or 2 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: IV: 1 g once daily (Roson 2001; Segev 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Proctitis, proctocolitis, enteritis (off-label use):</b> IM: 250 mg in a single dose plus oral doxycycline (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> IM: 250 mg as a single dose in combination with azithromycin plus metronidazole (or tinidazole) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection:</b> IV: <i>Streptococci, beta-hemolytic: </i> 2 g every 24 hours for 4 to 6 weeks (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pyelonephritis (acute, uncomplicated):</b> IV: 1 to 2 g once daily; after improvement, may be switched to an oral regimen to complete a 1- to 2-week treatment course (Grabe 2015). In females, some clinicians administer a single dose of 1 g before initiating oral outpatient empiric therapy (IDSA [Gupta 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Salmonellosis in HIV-infected patients (off-label use):</b> IV: 1 g every 24 hours. Duration of therapy in patients with CD4 count &ge;200 cells/mm<sup>3</sup> is 7 to 14 days (without concurrent bacteremia) or &ge;14 days (patients with concurrent bacteremia); patients with CD4 count &lt;200 cells/mm<sup>3</sup> should be treated for 2 to 6 weeks (regardless of presence of bacteremia) (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infection (off-label use) (IDSA [Stevens 2014]): Note:</b> Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to <i>Aeromonas hydrophilia:</i> IV: 1 to 2 g once daily in combination with doxycycline</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to <i>Vibrio vulnificus:</i> IV: 1 g once daily in combination with doxycycline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spontaneous bacterial peritonitis (prevention) (off-label use):</b> IV: 1 g once daily during active gastrointestinal bleeding (may be transitioned to an oral antibiotic after oral intake is resumed) for total duration of antibiotic therapy of 7 days (AASLD [Runyon 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis:</b> IV: 1 g 30 minutes to 2 hours before surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 1 g 30 minutes to 2 hours before surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 1 to 2 g within 60 minutes prior to surgery (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing for colorectal procedures:</i> 2 g within 60 minutes prior to surgery with concomitant metronidazole (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cholecystectomy:</i> 1 to 2 g every 12 to 24 hours, discontinue within 24 hours unless infection outside gallbladder suspected (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (intestinal or genitourinary tract surgery, surgery of axilla, or perineum) (off-label use):</b> IV: 1 g every 24 hours, in combination with metronidazole (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis in penicillin allergic patients (off-label use) (CDC [Workowski 2015]):</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Primary or secondary: 1 to 2 g once daily for 10 to 14 days (limited study data; optimal dose and duration have not been defined)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neurosyphilis: 2 g once daily for 10 to 14 days (limited study data)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Typhoid fever (off-label use):</b> IV: 2 g every 12 to 24 hours for 10 to 14 days; <b>Note:</b> Usually reserved for fluoroquinolone resistant disease (WHO 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Whipple disease (off-label use):</b> IV: Initial: 2 g once daily for 10 to 14 days, then oral therapy (sulfamethoxazole and trimethoprim preferred) (Feurle 2010; Feurle 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148227\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ceftriaxone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage range:</b> Infants, Children, and Adolescents: Usual dose: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild to moderate infections:</i> 50 to 75 mg/kg/day in 1 to 2 divided doses every 12 to 24 hours (maximum: 2,000 mg daily); continue until at least 2 days after signs and symptoms of infection have resolved</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Serious infections:</i> 80 to 100 mg/kg/day in 1 to 2 divided doses (maximum: 4,000 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization (off-label use):</b> IV: 50 mg/kg/day divided every 12 hours for 10 to 14 days (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial enteric infections in HIV-infected patients (empiric treatment) (off-label use):</b> Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia (CAP) (IDSA/PIDS [Bradley 2011]) (off-label dose):</b> Infants &gt;3 months and Children: IV: 50 to 100 mg/kg/day once daily or divided every 12 hours (maximum: 2,000 mg daily). <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. Use the higher end of the range for penicillin-resistant <i>S. pneumoniae</i>; in children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out; preferred in patients not fully immunized for <i>H. influenzae</i> type b and <i>S. pneumoniae</i>, or significant local resistance to penicillin in invasive pneumococcal strains.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, prophylaxis (off-label use): </b>Dental and upper respiratory procedures (patients allergic to penicillins and/or unable to take oral): Infants, Children, and Adolescents: IM, IV: 50 mg/kg 30 to 60 minutes prior to procedure; maximum dose: 1,000 mg/dose (AHA [Wilson 2007]; <i>Red Book</i> [AAP 2015]). <b>Note: </b>AHA guidelines (Baltimore 2015) limit the use of prophylactic antibiotics to patients at the highest risk for infective endocarditis (IE) or adverse outcomes (eg, prosthetic heart valves, patients with previous IE, unrepaired cyanotic congenital heart disease, repaired congenital heart disease with prosthetic material or device during first 6 months after procedure, repaired congenital heart disease with residual defects at the site or adjacent to site of prosthetic patch or device, and heart transplant recipients with cardiac valvulopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (off-label use): </b> Children and Adolescents: IV: 100 mg/kg/<b>day</b> divided every 12 hours <b>or</b> 80 mg/kg/dose every 24 hours; maximum daily dose: 4,000 mg/<b>day</b>, daily doses over 2,000 mg should be divided into 2 doses; treat for at least 4 weeks; longer durations may be necessary; may use in combination with other antibiotics based on organism (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epiglottis (off-label use):</b> IV: 100 mg/kg/day as a single dose on day 1, then 50 mg/kg as a single dose on day 2 (Sawyer 1994) or 75 mg/kg once daily for 10 to 14 days (Low 2003). Additional data may be necessary to further define the role of ceftriaxone in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bacteremia (off-label use) (CDC [Workowski 2015]):</i> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;45 kg: 50 mg/kg/dose once daily (maximum: 1,000 mg) for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg: 1,000 mg once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conjunctivitis (off-label use):</i> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates and Infants: 25 to 50 mg/kg/dose as a single dose (maximum dose: 125 mg) (CDC [Workowski 2015]). <b>Note:</b> Use contraindicated in hyperbilirubinemic neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Disseminated gonococcal infection (DGI) in infants including scalp abscess (off-label use):</i> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 25 to 50 mg/kg/dose once daily for 7 days (10 to 14 days for meningitis) (CDC [Workowski 2015]); <b>Note: </b>Use contraindicated in hyperbilirubinemic neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Disseminated gonococcal infection (arthritis, arthritis-dermatitis syndrome) (off-label use): </i>IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;45 kg: Arthritis: 50 mg/kg/dose once daily (maximum dose: 1,000 mg) for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg: Arthritis: 1,000 mg once daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endocarditis (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;45 kg: IM, IV: 50 mg/kg/day divided every 12 or 24 hours (maximum: 2,000 mg daily) for at least 28 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis (off-label use):</i> IV, IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 25 to 50 mg/kg/day in a single daily dose for 10 to 14 days (CDC [Workowski 2015]); <b>Note:</b> Use contraindicated in hyperbilirubinemic neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;45 kg: 50 mg/kg/day divided every 12 or 24 hours (maximum: 2,000 mg daily); usual duration of treatment is 10 to 14 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylactic treatment in neonates due to untreated maternal gonococcal infection (off-label use):</i> Neonates: IM, IV: 25 to 50 mg/kg as a single dose (maximum: 125 mg) (CDC [Workowski 2015]). <b>Note:</b> Use contraindicated in hyperbilirubinemic neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated gonorrhea (cervicitis, proctitis, or urethritis) (off-label population) CDC [Workowski 2015]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;45 kg: IM, IV: 25 to 50 mg/kg/dose as a single dose (maximum dose: 125 mg IM)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Uncomplicated gonorrhea: Pharyngitis or vulvovaginitis (off-label use) (CDC [Workowski 2015]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;45 kg: IM, IV: 25 to 50 mg/kg/dose as a single dose (maximum dose: 125 mg IM)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;45 kg and Adolescents: IM: 250 mg in a single dose plus oral azithromycin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lyme disease (off-label use): IM, IV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Atrioventricular heart block or carditis:</i> 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 to 21 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Encephalitis or other late neurologic disease:</i> 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 to 28 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurologic:</i> 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 days (Halperin 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis:</i> 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 to 21 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Recurrent arthritis:</i> 50 to 75 mg/kg once daily (maximum: 2,000 mg) for 14 to 28 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis (empiric treatment): </b> IM, IV: Loading dose of 100 mg/kg (maximum: 4,000 mg), followed by:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 100 mg/kg/day divided every 12 to 24 hours (maximum: 4,000 mg daily); usual duration of treatment is 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i> 80 to 100 mg/kg/day divided every 12 to 24 hours (maximum: 4,000 mg daily) (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease, invasive, high-risk patient contacts (chemoprophylaxis) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents &lt;15 years: IM: 125 mg in a single dose (CDC 2005; <i>Red Book</i> [AAP 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otitis media:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Acute:</i> 50 mg/kg in a single dose (maximum: 1,000 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Persistent or relapsing (off-label dose):</i> 50 mg/kg once daily for 3 days (AAP 2014; Lieberthal 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Salmonellosis in HIV-infected patients (off-label use)</b>: Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Shigella dysentery type 1 (off-label dose):</b> IM: 50 to 100 mg/kg/day for 2 to 5 days (WHO 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin/skin structure infections:</b> IM, IV: 50 to 75 mg/kg/day in 1 to 2 divided doses (maximum: 2,000 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical (perioperative) prophylaxis (off-label dose):</b> Children &ge; 1 year: IV: 50 to 75 mg/kg within 60 minutes prior to surgery (maximum: 2,000 mg) (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Typhoid fever (off-label use):</b> IV: 80 mg/kg once daily for 14 days (Stephens 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148204\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148205\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, in patients with concurrent renal and hepatic impairment, maximum daily dose should not exceed 2 g.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">ESRD requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148206\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, in patients with concurrent renal and hepatic impairment, maximum daily dose should not exceed 2 g.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148175\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (50 mL); 40 mg/mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocephin: 500 mg (1 ea [DSC]); 1 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 100 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148159\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148179\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject deep IM into large muscle mass; a concentration of 250 mg/mL or 350 mg/mL is recommended for all vial sizes except the 250 mg size (250 mg/mL is suggested); can be diluted with 1:1 water or 1% lidocaine for IM administration only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse as an intermittent infusion over 30 minutes. IV push administration over 1 to 4 minutes has been reported in children &ge;12 years, adolescents, and adults (concentration: 100 mg/mL), primarily in patients outside the hospital setting (Baumgartner 1983; Garrelts 1988; Poole 1999), although a 2 g dose administered IV push over 5 minutes resulted in tachycardia, restlessness, diaphoresis, and palpitations in one patient (Lossos 1994). IV push administration in young infants may also have been a contributing factor in risk of cardiopulmonary events occurring from interactions between ceftriaxone and calcium (Bradley 2009). Do not coadminister with calcium-containing solutions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148178\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute bacterial otitis media:</b> Caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (including beta-lactamase-producing strains), or <i>Moraxella catarrhalis</i> (including beta-lactamase-producing strains).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial septicemia:</b> Caused by <i>Staphylococcus aureus</i>, <i>S. pneumoniae</i>, <i>Escherichia coli</i>, <i>H. influenzae</i>, or <i>Klebsiella pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections:</b> Caused by <i>S. aureus</i>, <i>S. pneumoniae</i>, <i>E. coli</i>, <i>Proteus mirabilis</i>, <i>K. pneumoniae</i>, or <i>Enterobacter</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections:</b> Caused by <i>E. coli</i>, <i>K. pneumoniae</i>, <i>Bacteroides fragilis</i>, <i>Clostridium</i> spp., or <i>Peptostreptococcus</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections:</b> Caused by <i>S. pneumoniae</i>, <i>S. aureus</i>, <i>H. influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>K. pneumoniae</i>, <i>E. coli</i>, <i>Enterobacter aerogenes</i>, <i>P. mirabilis</i>, or <i>Serratia marcescens</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis:</b> Caused by <i>H. influenzae</i>, <i>Neisseria meningitidis</i>, or <i>S. pneumoniae</i>. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by <i>Staphylococcus epidermidis</i> and <i>E. coli</i> (efficacy for these 2 organisms in this organ system was studied in fewer than 10 infections).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease:</b> Caused by <i>N. gonorrhoeae</i>. Ceftriaxone, like other cephalosporins, has no activity against <i>Chlamydia trachomatis</i>. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and <i>C. trachomatis</i> is one of the suspected pathogens, appropriate antichlamydial coverage should be added.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections:</b> Caused by <i>S. aureus</i>, <i>S. epidermidis</i>, <i>Streptococcus pyogenes</i>, viridans group streptococci, <i>E. coli</i>, <i>Enterobacter cloacae</i>, <i>Klebsiella oxytoca</i>, <i>K. pneumoniae</i>, <i>P. mirabilis</i>, <i>Morganella morganii</i> (efficacy for this organism in this organ system was studied in fewer than 10 infections), <i>Pseudomonas aeruginosa</i>, <i>S. marcescens</i>, <i>Acinetobacter calcoaceticus</i>, or <i>B. fragilis</i> (efficacy for this organism in this organ system was studied in fewer than 10 infections), or <i>Peptostreptococcus</i> spp.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis:</b> Reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (eg, vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those older than 70 years, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice, or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (eg, during coronary artery bypass surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uncomplicated gonorrhea (cervical/urethral and rectal):</b> Caused by <i>N. gonorrhoeae</i>, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of <i>N. gonorrhoeae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (complicated and uncomplicated):</b> Caused by <i>E. coli</i>, <i>P. mirabilis</i>, <i>Proteus vulgaris</i>, <i>M. morganii</i>, or <i>K. pneumoniae</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474850\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis; Arthritis, septic (adults); Bacterial enteric infections in HIV-infected patients (empiric treatment) (adolescents and adults); Bite wounds (animal); Brain abscess (adults); Chancroid; Community-acquired pneumonia (children); Endocarditis, treatment (adults); Endocarditis, treatment (pediatric); Endocarditis, prophylaxis; Epididymitis; Epiglottitis (children); Gonococcal bacteremia, meningitis and endocarditis; Gonococcal conjunctivitis; Gonorrhea, disseminated infections (including arthritis and arthritis-dermatitis syndrome); Gonorrhea, infant prophylaxis (due to untreated maternal gonococcal infection); Gonorrhea, uncomplicated infections of the pharynx and vulvovaginitis; Lyme disease; Meningococcal disease, invasive, high-risk patient contacts (chemoprophylaxis); Neurosyphilis in penicillin-allergic patients; Osteomyelitis, native vertebral; Proctitis, proctocolitis, enteritis; Prophylaxis against sexually transmitted diseases following sexual assault; Prosthetic joint infection (adults); Salmonellosis in HIV-infected patients (adolescents and adults); Shigellosis; Skin and soft tissue necrotizing infections due to Aeromonas hydrophilia or Vibrio vulnificus; Spontaneous bacterial peritonitis (prevention); Surgical site infections; Syphilis (primary and secondary) in penicillin allergic patients; Typhoid fever; Whipple disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148257\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CefTRIAXone may be confused with ceFAZolin, cefoTEtan, cefOXitin, cefTAZidime, Cetraxal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocephin may be confused with Roferon</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148166\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin tightness (IM: &le;5% to &le;17%; local)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Induration at injection site (&le;5% to &le;17%; incidence higher with IM), warm sensation at injection site (IM: &le;5% to &le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (6%), thrombocythemia (5%), leukopenia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (&le;1%), tenderness at injection site (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute generalized exanthematous pustulosis, acute renal failure (post-renal), agranulocytosis, allergic dermatitis, anaphylactoid reaction, anaphylaxis, anemia, basophilia, blood coagulation disorder, bronchospasm, candidiasis, casts in urine, chills, choledocholithiasis, cholelithiasis, clostridium difficile associated diarrhea, colitis, decreased prothrombin time, diaphoresis, dizziness, dysgeusia, dyspepsia, edema, epistaxis, erythema multiforme, fever, flatulence, flushing, gallbladder sludge, glossitis, glycosuria, granulocytopenia, headache, hematuria, hemolytic anemia, hypersensitivity pneumonitis, increased monocytes, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, jaundice, kernicterus, leukocytosis, lymphocytopenia, lymphocytosis, nausea, nephrolithiasis, neutropenia, oliguria, palpitations, pancreatitis, phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, seizure, serum sickness, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis, ureteral obstruction, urogenital fungal infection, urolithiasis, urticaria, vaginitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148182\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ceftriaxone, any component of the formulation, or other cephalosporins; <b>do not use in hyperbilirubinemic neonates</b>, particularly those who are premature since ceftriaxone is reported to displace bilirubin from albumin binding sites; concomitant use with intravenous calcium-containing solutions/products in neonates (&le;28 days); IV use of ceftriaxone solutions containing lidocaine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148163\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Serious and sometimes fatal hypersensitivity has been reported. Use caution in patients with a history of any allergy (particularly drugs), penicillin allergy or beta-lactam sensitivity. If severe hypersensitivity occurs, discontinue immediately and institute supportive emergency measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elevated INR: May be associated with increased INR (rarely), especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease. Monitor INR during treatment if patient has impaired synthesis or low stores of vitamin K; supplementation may be needed if clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolytic anemia: Severe cases (including some fatalities) of immune-related hemolytic anemia have been reported in patients receiving cephalosporins, including ceftriaxone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Secondary to biliary obstruction, pancreatitis has been reported rarely. Most patients had biliary stasis or sludge risk factors (eg, preceding major surgery, sever illness, TPN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gallbladder pseudolithiasis: Abnormal gallbladder sonograms have been reported, possibly due to ceftriaxone-calcium precipitates; probability is greatest in pediatric patients. Discontinue in patients who develop signs and symptoms and/or sonographic evidence of gallbladder disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with a history of GI disease, especially colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal/hepatic impairment (concurrent) Use with caution in patients with concurrent hepatic dysfunction and significant renal disease; dosage should not exceed 2 g/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neonates: Use extreme caution in neonates due to risk of hyperbilirubinemia, particularly in premature infants (contraindicated in hyperbilirubinemic neonates and neonates &lt;41 weeks postmenstrual age). Fatal precipitation reactions in neonates due to coadministration of calcium-containing solutions have been reported; concurrent use in neonates is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Precipitation: Ceftriaxone may complex with calcium causing precipitation. Fatal lung and kidney damage associated with calcium-ceftriaxone precipitates has been observed in premature and term neonates. Due to reports of precipitation reaction in neonates, do not reconstitute, admix, or coadminister with calcium-containing solutions (eg, LR, Hartmann&rsquo;s solution, parenteral nutrition), even via separate infusion lines/sites or at different times in any neonate. Ceftriaxone should not be diluted or administered simultaneously with any calcium-containing solution via a Y-site in any patient. However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another for use in patients <b>other than neonates</b> if infusion lines are thoroughly flushed (with a compatible fluid) between infusions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298998\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148168\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9229&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts (Intravenous): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ringer's Injection (Lactated): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium in the Lactated Ringer's forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions (including LR) within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148171\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5952824\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ceftriaxone crosses the placenta. Pregnancy was found to influence the single dose pharmacokinetics of ceftriaxone when administered prior to delivery (Popovi&#263; 2007). The pharmacokinetics of ceftriaxone following multiple doses in the third trimester are similar to those of nonpregnant patients (Bourget Fernandez 1993). Ceftriaxone is recommended for use in pregnant women for the treatment of gonococcal infections, Lyme disease, and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (consult current guidelines) (ACOG 120, 2011; CDC [Workowski 2015]; Wormser 2006). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148184\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ceftriaxone is excreted into breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of ceftriaxone is 1.2% to 2.4% when calculated using the highest breast milk concentration located and compared to a therapeutic infant dose of 50 to 100 mg/kg/day. In general, breast-feeding is considered acceptable when the relative infant dose is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (7.89 mcg/mL), the estimated daily infant dose via breast milk is 1.2 mg/kg/day. This milk concentration was obtained following a maternal dose of ceftriaxone 2 g/day on postpartum day 2 (day 7 of antimicrobial therapy) (Bourget 1993).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The elimination half-life in breast milk following administration of a single dose of ceftriaxone 1 g was 12.8 hours and 17.3 hours with IV and IM administration, respectively (Kafetzis 1983).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002). Ceftriaxone is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002). The manufacturer recommends that caution be exercised when administering ceftriaxone to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148185\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148173\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prothrombin time/INR. Observe for signs and symptoms of anaphylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148162\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148181\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body including gallbladder, lungs, bone, bile, CSF (higher concentrations achieved when meninges are inflamed); V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 0.34 to 0.55 L/kg (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: 0.3 to 0.4 L/kg (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~6 to 14 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 85% to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (Martin 1984): 1 to 4 days: 16 hours; 9 to 30 days: 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (age not specified): 4.1 to 6.6 hours (Richards 1984) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal and hepatic function: ~5 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Renal impairment (mild-to-severe): ~12 to 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (33% to 67% as unchanged drug); feces (as inactive drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323052\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CefTRIAXone Sodium in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (50 mL): $18.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (50 mL): $40.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $9.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $240.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $15.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $2.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $46.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $8.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $33.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CefTRIAXone Sodium-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g 3.74% (1): $13.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g 2.22% (1): $22.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F148186\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acantex (AR, CL);</li>\n      <li>Aciphin (BD);</li>\n      <li>Acrocef (EC);</li>\n      <li>Actaxon (ID);</li>\n      <li>Alcizon (ET);</li>\n      <li>Amcef (MX);</li>\n      <li>Aumax (VN);</li>\n      <li>Aurofox (MX);</li>\n      <li>Aurokson (UA);</li>\n      <li>Axone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Axtar (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Benaxona (MX);</li>\n      <li>Biotriax (ID);</li>\n      <li>Broadced (ID);</li>\n      <li>Brospec (ID);</li>\n      <li>Cafalogen (PE);</li>\n      <li>Carotan (PE);</li>\n      <li>Cef-S (PH);</li>\n      <li>Cef-Zone (TH);</li>\n      <li>Cefacrol (PE);</li>\n      <li>Cefaxona (MX);</li>\n      <li>Cefaxone (MY, SG);</li>\n      <li>Cefin (SG);</li>\n      <li>Cefizon (LK);</li>\n      <li>Cefkizon (KR);</li>\n      <li>Cefort (RO);</li>\n      <li>Cefraden (MX);</li>\n      <li>Cefriex (ID);</li>\n      <li>Ceftash (ET);</li>\n      <li>Ceftral (LK);</li>\n      <li>Ceftrex (MX, TH);</li>\n      <li>Ceftrian (EC);</li>\n      <li>Ceftrianol (MX);</li>\n      <li>Ceftriax-1 (PH);</li>\n      <li>Ceftrifil (PH);</li>\n      <li>Ceftrilem (MX);</li>\n      <li>Ceftritina (VN);</li>\n      <li>Ceftron (LK);</li>\n      <li>Cefxon (ID);</li>\n      <li>Celltriaxon (MY);</li>\n      <li>Ceptaxone (KR);</li>\n      <li>Cerixon (KR);</li>\n      <li>Cetriaf (DO);</li>\n      <li>Chef (TW);</li>\n      <li>Cikedrix (PH);</li>\n      <li>Ecotrixon (ID);</li>\n      <li>Elpicef (ID);</li>\n      <li>Eroxet (PH);</li>\n      <li>Erphacef (ID);</li>\n      <li>Excephin (ET);</li>\n      <li>Exempla (AR);</li>\n      <li>Ferfacef (ID);</li>\n      <li>Forgram (PH);</li>\n      <li>Gomcephin (KR);</li>\n      <li>Infecef (BD);</li>\n      <li>Ivixone (TZ);</li>\n      <li>Keftriaxone (IL);</li>\n      <li>Keptrix (PH);</li>\n      <li>Lendacin (HR, HU);</li>\n      <li>Longacef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Lyceft (IN);</li>\n      <li>Megion (AE, BH, CR, GT, HN, JO, KW, LB, MX, NI, PA, PH, QA, SA, SV);</li>\n      <li>Mesporin (AE, BF, BH, BJ, CI, CY, EE, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Mesporin IM (BB, BM, BS, BZ, GY, HK, JM, PR, SR);</li>\n      <li>Mesporin IV (BB, BM, BS, BZ, GY, HK, JM, PR, SR);</li>\n      <li>Monocef (IN);</li>\n      <li>Newcef (KR);</li>\n      <li>Novosef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, RU, SA, SY, TR, YE);</li>\n      <li>Oframax (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Oncef (PH);</li>\n      <li>Pantrixon (PH);</li>\n      <li>Powergef (TZ);</li>\n      <li>Protsef (UA);</li>\n      <li>Retrokor (PH);</li>\n      <li>Rocefin (BR, CO, IT);</li>\n      <li>Rocefort (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rocephalin (DK, FI, IS, NO, SE);</li>\n      <li>Rocephin &quot;Roche&quot; (CZ);</li>\n      <li>Rocephin (AE, AT, BH, CH, CN, CU, CY, DE, EC, EG, GB, GH, GR, HK, HR, HU, IE, IL, IQ, IR, JO, JP, KE, KR, KW, LB, LV, LY, MT, MX, NL, OM, PE, PH, PK, PL, PT, PY, QA, RO, SA, SG, SY, TH, TW, TZ, UG, UY, VE, VN, YE, ZM);</li>\n      <li>Rocephin Roche (CZ);</li>\n      <li>Rocephine (BE, FR, LU);</li>\n      <li>Rocidar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Rotsefin (UA);</li>\n      <li>Roxcef (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Samixon (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Sintrex (TW);</li>\n      <li>Socef (ID);</li>\n      <li>Tacex (MX);</li>\n      <li>Terbac (MX);</li>\n      <li>Tercef (BG);</li>\n      <li>Tracef (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Traxef (BD);</li>\n      <li>Traxol (ZW);</li>\n      <li>Trexofin (SG);</li>\n      <li>Triaken (MX);</li>\n      <li>Triax (IL);</li>\n      <li>Triax-1 (PH);</li>\n      <li>Triaxone (AE, ET, KR, KW, LB, QA, SA, SG);</li>\n      <li>Tricef (TW);</li>\n      <li>Tricefin (SG);</li>\n      <li>Trijec (ID);</li>\n      <li>Triox (MX);</li>\n      <li>Trixone (MY);</li>\n      <li>Trizon (BD);</li>\n      <li>Tsefast (UA);</li>\n      <li>U-Ron (TW);</li>\n      <li>Unocef (MY);</li>\n      <li>Utrixone (ZW);</li>\n      <li>Vaxcel (LK);</li>\n      <li>Veracol (NZ);</li>\n      <li>Viatrex (PH);</li>\n      <li>Xone (ZW);</li>\n      <li>Xtenda (PH);</li>\n      <li>Zefone 250 (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Zeftrox (LK);</li>\n      <li>Zontrixone (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"AAP.2012\"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2011 Jun;117(6):1472-83. doi: 10.1097/AOG.0b013e3182238c31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span><span class=\"doi\">10.1097/AOG.0b013e3182238c31</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 61, 153.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baumgartner JD and Glauser MP, &quot;Single Daily Dose Treatment of Severe Refractory Infections With Ceftriaxone. Cost Savings and Possible Parenteral Outpatient Treatment,&quot; <i>Arch Intern Med</i>, 1983, 143(10):1868-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/6312914/pubmed\" target=\"_blank\" id=\"6312914\">6312914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bourget P, Fernandez H, Quinquis V, Delouis C. Pharmacokinetics and protein binding of ceftriaxone during pregnancy. <i>Antimicrob Agents Chemother.</i> 1993;37(1):54-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/8431018/pubmed\" target=\"_blank\" id=\"8431018\">8431018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Wassel RT, Lee L, et al, &ldquo;Intravenous Ceftriaxone and Calcium in the Neonate Assessing the Risk for Cardiopulmonary Adverse Events, Pediatrics, 2009, 123(4):e609-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/19289450/pubmed\" target=\"_blank\" id=\"19289450\">19289450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Compogiannis LS, Murray WE, et al, &ldquo;Pharmacokinetics and Safety of Intramuscular Injection of Concentrated Ceftriaxone in Children,&rdquo; <i>Clin Pharm</i>, 1992, 11(11):961-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/1464221/pubmed\" target=\"_blank\" id=\"1464221\">1464221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25075836\"></a>Brouwer MC, Tunkel AR, McKhann GM, et al. Brain abscess. <i>New Engl J Med</i>. 2014;371:447-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/25075836/pubmed\" target=\"_blank\" id=\"25075836\">25075836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceftriaxone for injection [prescribing information]. Lake Forest, IL: Hospira Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15917737\"></a>Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2005;54(RR-7):1-17. Available at <a href=\"http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/15917737/pubmed\" target=\"_blank\" id=\"15917737\">15917737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24703397\"></a>Coiffier G, Alber JD. Is ceftriaxone 2g once daily a valid treatment option for osteoarticular infections due to Staphylococcus spp., Streptococcus spp., and gram negative rods? <i>Joint Bone Spine</i>. 2014;81:200-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/24703397/pubmed\" target=\"_blank\" id=\"24703397\">24703397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Committee on Adolescence, AAP, &ldquo;Sexual Assault and the Adolescent,&rdquo; <i>Pediatrics</i>, 1994, 94(5):761-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/7936916/pubmed\" target=\"_blank\" id=\"7936916\">7936916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connor BA and Schwartz E, &ldquo;Typhoid and paratyphoid Fever in Travellers,&rdquo; <i>Lancet Infect Dis</i>, 2005, 5(10):623-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/16183516/pubmed\" target=\"_blank\" id=\"16183516\">16183516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18500456\"></a>Dalla Vestra M, Rettore C, Sartore P, et al. Acute septic arthritis: remember gonorrhea. <i>Rheum Int</i>. 2008;29:81-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/18500456/pubmed\" target=\"_blank\" id=\"18500456\">18500456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deeter RG, Weinstein MP, Swanson KA, et al, &ldquo;Crossover Assessment of Serum Bactericidal Activity and Pharmacokinetics of Five Broad-Spectrum Cephalosporins in the Elderly,&rdquo; <i>Antimicrob Agents Chemother</i>, 1990, 34(6):1007-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/2393258/pubmed\" target=\"_blank\" id=\"2393258\">2393258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11272029\"></a>de Louvois J, et al. The rational use of antibiotics in the treatment of brain abscess: report by the infection in neurosurgery working party of the British Society for Antimicrobial Chemotherapy (BSAC). <i>Br J Neurosurg</i>. 2000;14:525-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/11272029/pubmed\" target=\"_blank\" id=\"11272029\">11272029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell SF, Butler JC, Giebink GS, et al, &ldquo;Acute Otitis Media: Management and Surveillance in an Era of Pneumococcal Resistance - A Report From the Drug-Resistant <i>Streptococcus pneumoniae</i> Therapeutic Working Group,&rdquo; <i>Pediatr Infect Dis J</i>, 1999, 18(1):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/9951971/pubmed\" target=\"_blank\" id=\"9951971\">9951971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenollar F, Pu&eacute;chal X, and Raoult D, &ldquo;Whipple's Disease,&rdquo; <i>N Engl J Med</i>, 2007, 356(1):55-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/17202456/pubmed\" target=\"_blank\" id=\"17202456\">17202456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19879276\"></a>Feurle G, Junga N, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple&rsquo;s disease. <i>Gastroenterology</i>. 2010;138:478-486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/19879276/pubmed\" target=\"_blank\" id=\"19879276\">19879276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23291038\"></a>Feurle GE, Moos V, Blacker H, et al. Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim sulfamethoxazole in Whipple&rsquo;s disease. <i>J Infect</i>. 2013;66:263-270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/23291038/pubmed\" target=\"_blank\" id=\"23291038\">23291038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frenck RW Jr, Nakhla I, Sultan Y, et al, &ldquo;Azithromycin Versus Ceftriaxone for the Treatment of Uncomplicated Typhoid Fever in Children,&rdquo; <i>Clin Infect Dis</i>, 2000, 31(5):1134-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/11073741/pubmed\" target=\"_blank\" id=\"11073741\">11073741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frenkel LD, &ldquo;Once-Daily Administration of Ceftriaxone for the Treatment of Selected Serious Bacterial Infections in Children,&rdquo; <i>Pediatrics</i>, 1988, 82(3 Pt 2):486-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/3405685/pubmed\" target=\"_blank\" id=\"3405685\">3405685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrelts JC, Ast D, LaRocca J, et al, &quot;Postinfusion Phlebitis After Intravenous Push versus Intravenous Piggyback Administration of Antimicrobial Agents,&quot; <i>Clin Pharm</i>, 1988, 7(10):760-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/3233896/pubmed\" target=\"_blank\" id=\"3233896\">3233896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on Urological Infections. 2015. Available at https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21292654\"></a>Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/21292654/pubmed\" target=\"_blank\" id=\"21292654\">21292654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al. Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2007;69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18178705\"></a>Harwood MI, Womack J, Kaptur R. Primary meningococcal arthritis. <i>J Amer Board Fam Med</i>. 2008;21:66-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/18178705/pubmed\" target=\"_blank\" id=\"18178705\">18178705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hayton WL and Stoeckel K, &ldquo;Age-Associated Changes in Ceftriaxone Pharmacokinetics,&rdquo; <i>Clin Pharmacokinet</i>, 1986, 11(1):76-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/3948454/pubmed\" target=\"_blank\" id=\"3948454\">3948454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed December 21, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kafetzis DA, Brater DC, Fanourgakis JE, Voyatzis J, Georgakopoulos P. Ceftriaxone distribution between maternal blood and fetal blood and tissues at parturition and between blood and milk postpartum. <i>Antimicrob Agents Chemother</i>. 1983;23(6):870-873.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/6311089/pubmed\" target=\"_blank\" id=\"6311089\">6311089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroh UF, Lennartz H, Edwards DJ, et al, &ldquo;Pharmacokinetics of Ceftriaxone in Patients Undergoing Continuous Veno-Venous Hemofiltration,&rdquo; <i>J Clin Pharmacol</i>, 1996, 36(12):1114-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/9013367/pubmed\" target=\"_blank\" id=\"9013367\">9013367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. <i>Pediatrics</i>. 2013;131(3):e964-999. Errata appears in <i>Pediatrics</i>. 2014;133(2):346-347.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lossos IS and Lossos A., &quot;Hazards of Rapid Administration of Ceftriaxone,&quot; <i>Ann Pharmacother</i>, 1994, 28(6):807-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/7919578/pubmed\" target=\"_blank\" id=\"7919578\">7919578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15024460\"></a>Low YM, Leong JL, and Tan HKK, &ldquo;Paediatric Acute Epiglottitis Re-Visited,&rdquo; <i>Singapore Med J</i>, 2003, 44(10): 539-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/15024460/pubmed\" target=\"_blank\" id=\"15024460\">15024460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/10069359/pubmed\" target=\"_blank\" id=\"10069359\">10069359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23223583\"></a>Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin E, Koup JR, Paravicini U, et al, &quot;Pharmacokinetics of Ceftriaxone in Neonates and Infants With Meningitis,&quot; <i>J Pediatr</i>, 1984, 105(3):475-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/6088747/pubmed\" target=\"_blank\" id=\"6088747\">6088747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poole S, Nowobilski-Vasilios A, and Free F, &ldquo;Intravenous Push Medications in the Home,&rdquo; <i>J Intraven Nurs</i>, 1999, 22(4):209-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/10476138/pubmed\" target=\"_blank\" id=\"10476138\">10476138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Popovi&#263; J, Gruji&#263; Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. <i>J Clin Pharm Ther</i>. 2007;32(6):595-602.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/18021337/pubmed\" target=\"_blank\" id=\"18021337\">18021337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15505773\"></a>Raad J, Peacock JE. Septic arthritis in the adult caused by Streptococcus pneumoniae: a report of 4 cases and review of the literature. <i>Semin Arthritis Rheum</i>. 2004;34:559-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/15505773/pubmed\" target=\"_blank\" id=\"15505773\">15505773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richards DM, Heel RC, Brogden RN, et al, &ldquo;Ceftriaxone: A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use,&rdquo; <i>Drugs</i>, 1984, 27(6):469-527.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/6329638/pubmed\" target=\"_blank\" id=\"6329638\">6329638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocephin (ceftriaxone sodium) [prescribing information]. South San Francisco, CA: Genentech; Received June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11310807\"></a>Roson B, Carratala J, Tubau F. Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. <i>Microb Drug Resist</i>. 2001;7(1):85-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/11310807/pubmed\" target=\"_blank\" id=\"11310807\">11310807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.23463403</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8129435\"></a>Sawyer SM, Johnson PD, Hogg GG, et al, &ldquo;Successful Treatment of Epiglottitis With Two Doses of Ceftriaxone,&rdquo; <i>Archives of Disease in Childhood</i>, 1994, 70(2):129-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/8129435/pubmed\" target=\"_blank\" id=\"8129435\">8129435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaad UB, Suter S, Gianella-Borradori A, et al, &ldquo;A Comparison of Ceftriaxone and Cefuroxime for the Treatment of Bacterial Meningitis in Children,&rdquo; <i>N Engl J Med</i>, 1990, 322(3):141-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/2403654/pubmed\" target=\"_blank\" id=\"2403654\">2403654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8605897\"></a>Segev S, Raz R, Rubinstein E, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. <i>Eur J Clin Microbiol Infect Dis</i>. 1995;14(10):851-855.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/8605897/pubmed\" target=\"_blank\" id=\"8605897\">8605897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shen-Hua W, Fan-Yi M, Qing-Ling Z, Li-Na Z, Li-Jun M. Ceftriaxone-associated renal toxicity in adults: a case report and recommendations for the management of such cases. <i>J Clin Pharm Ther</i>. 2016;41(3):348-350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/26913690/pubmed\" target=\"_blank\" id=\"26913690\">26913690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 15;50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stamm WE, Hooton TM. Management of urinary tract infections in adults. <i>N Engl J Med</i>. 1993;329(18):1328-1334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/8413414/pubmed\" target=\"_blank\" id=\"8413414\">8413414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11840084\"></a>Stephens I and Levine MM, &ldquo;Management of Typhoid Fever in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 2002, 21(2): 157-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/11840084/pubmed\" target=\"_blank\" id=\"11840084\">11840084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo; <i>Circulation</i>, 2007, 115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/17446442/pubmed\" target=\"_blank\" id=\"17446442\">17446442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &ldquo;Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae Type 1&rdquo;, 2005. Available at http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf?ua=1</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidelines for the Treatment of<i> Neisseria gonorrhoeae.</i> Geneva, Switzerland: World Health Organization; 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/27512795/pubmed\" target=\"_blank\" id=\"27512795\">27512795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). The diagnosis, treatment and prevention of typhoid fever. 2003. Available at http://apps.who.int/iris/bitstream/10665/68122/1/WHO_V-B_03.07_eng.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(9):1089-134. Epub 2006 Oct 2. Erratum in: <i>Clin Infect Dis</i>. 2007;45(7):941.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ceftriaxone-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9229 Version 224.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F148198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F148199\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F148250\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F148203\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F148227\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F148204\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F148205\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F148206\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F148175\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F148159\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F148179\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F148178\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474850\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F148257\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F148166\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F148182\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F148163\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298998\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F148168\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F148171\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5952824\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F148184\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F148185\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F148173\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F148162\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F148181\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323052\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F148186\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9229|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ceftriaxone-patient-drug-information\" class=\"drug drug_patient\">Ceftriaxone: Patient drug information</a></li><li><a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftriaxone: Pediatric drug information</a></li></ul></div></div>","javascript":null}